436,956 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Man Group plc

Man Group plc bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 436,956 shares of the biopharmaceutical company’s stock, valued at approximately $272,460,000.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $226,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $3,183,000. Gabelli Funds LLC raised its position in shares of Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after purchasing an additional 55 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in Regeneron Pharmaceuticals by 18.8% in the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after purchasing an additional 5,120 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: An analysis titled “Regeneron: Why I Still See Upside After the Rally” reflects a continued bullish view of REGN’s long-term prospects following its recent advance. Regeneron: Why I Still See Upside After the Rally
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day short-interest ratio. However, the figures appear incomplete or erroneous, making them unsuitable as a meaningful trading signal.
• Negative Sentiment: Several law firms publicized a securities-fraud class action tied to Regeneron’s Phase 3 melanoma-therapy trial failure. The trial disclosure reportedly triggered a sharp selloff and erased approximately $11 billion in market value; the lawsuit alleges investors were harmed by inadequate or misleading disclosures. A September 14, 2026 deadline applies to investors seeking lead-plaintiff status. Notices were issued by Hagens Berman, Pomerantz, SueWallSt, and Portnoy Law.
• Negative Sentiment: Additional law firms, including Faruqi & Faruqi, Schall Brown & Schwartz, and Levi & Korsinsky, reiterated the pending litigation and encouraged affected shareholders to participate. The repeated announcements increase near-term legal and reputational overhang, although they do not represent new operating developments. Faruqi & Faruqi notice

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock worth $1,090,030 over the last three months. 6.97% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

REGN has been the topic of several research analyst reports. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Canaccord Genuity Group lowered their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, HSBC cut their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $801.70.

Regeneron Pharmaceuticals Trading Up 0.6%

REGN stock opened at $833.56 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $847.00. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a market cap of $85.82 billion, a P/E ratio of 20.60, a PEG ratio of 1.41 and a beta of 0.22. The company’s 50-day simple moving average is $705.74 and its 200-day simple moving average is $717.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $12.81 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.